Meta-analysis of clinical efficacy and safety comparison of PEG-rhG-CSF and rhG-CSF for the prevention of febrile neutropenia associated with chemotherapy
HUANG Li
LIU Ke
LUO Sheng-ping
TAN Qiu-hong
Abstract：Objective: To compare the clinical efficacy and safety of PEG-rhG-CSF and rhG-CSF used in patients with solid tumors and malignant lymphomas for the prevention of febrile neutropenia (FN) associated with chemotherapy. Methods:Randomized controlled trials (RCTs) focusing on the efficacy and safety comparison of PEG-rhG-CSF versus rhG-CSF were searched in databases including Cochrane Library, PubMed, EMBase, CBM, CNKI, VIP and Wanfang database from construction to December 21st, 2017. Meta-analysis was conducted by the RevMan 5.3 software. Results: A total of 10 RCTs were enrolled in this study. A single dose of PEG-rhG-CSF per cycle versus daily rhG-CSF, meta analysis results were as follows: the incidence rate of FN: OR = 0.58, 95%CI[0.34, 1.00] for cycle one and OR = 0.76, 95%CI[0.52, 1.11] for all cycles. The incidence rate of grade Ⅳneutropenia rates: OR = 0.93, 95%CI[0.62, 1.39] for cycle one, OR = 0.77, 95%CI[0.50, 1.20] for cycle two, OR = 0.65, 95%CI[0.23, 1.78] for cycle three and OR = 0.79, 95%CI[0.51, 1.22] for cycle four. Duration of grade Ⅳ neutropenia:MD = – 0.01, 95%CI[– 0.28, 0.26] for cycle one, MD = – 0.14, 95%CI[– 0.54, 0.26] for cycle two, MD = – 0.21, 95%CI[– 0.99, 0.57] for cycle three and MD = – 0.22, 95%CI[– 0.61, 0.17] for cycle four. Incidence of bone pain: OR = 0.81, 95%CI[0.60, 1.09]. There were no significant differences in outcome indexes between two groups. Conclusion: Both single dose of PEG-rhG-CSF and continunous daily injection of rhG-CSF for patients undergoing myelosuppressive chemotherapy had equivalent incidence rate of FN, grade Ⅳ neutropenia and duration bone pain.
Keywords：PEG-rhG-CSFrhG-CSFFebrile neutropeniaMeta-analysis
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 264-269 )